Peritoneal Ultrafiltration in Cardio Renal Syndrome.

Congestive Heart Failure Clinical Trial

— PURE  

Official title:

Peritoneal Ultrafiltration in Cardio Renal Syndrome to Prevent Heart Failure Exacerbation.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03994874
• Other study ID #: CQ012019
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: July 2024
• Est. completion date: March 2026

Study information

• Verified date: May 2024
• Source: Iperboreal Pharma Srl
• Contact: Arduino Arduini, MD
• Phone: +41 79 7878312
• Email: a.arduini[@]corequest.ch
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Randomized, controlled, unblinded, adaptive design clinical trial to evaluate the safety and efficacy of PolyCore (Polydextrin, L-Carnitine, D-xylitol) peritoneal ultrafiltration (PUF) in patients with heart failure and reduced ejection fraction (HFrEF).

Description:

The study will include adults HFrEF patients, that despite guidelines directed medical therapy still retain a congestive heart failure (HF) picture. During the study, patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change. Patients will be assigned randomly to receive either PolyCore PUF (over the top of their prescribed heart failure medications), for 6 months, or to the control arm receiving stable medical therapy according to international guidelines and comprehensive of loop diuretic (furosemide) dose till to 2.5mg/kg/day, without PUF therapy. The PUF ultrafiltration will be performed with a single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours, for 6 months. An independent data safety monitoring board (DSMB) will be convened for this study and will review the results of the trial at regular intervals to protect patients participating in the study. An adaptive interim analysis will be performed when in each group 20 patients have completed 6 months in the study, for analysis of the primary outcome. The purpose of the adaptive interim analysis is to calculate the final study sample size.The DSMB will closely examine the interim primary efficacy results, respecting the confidentiality and integrity of data, to investigate the final sample sizes necessary to complete the study.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 84
• Est. completion date: March 2026
• Est. primary completion date: November 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age =18 yrs
• Left ventricular ejection fraction =60%
• NYHA Classification of III-IV despite guidelines directed medical therapy
• Right ventricular failure due to after load mismatch, addressed by the presence of tricuspid calve regurgitation (= moderate) and by the disproportioned increase of the right atrial pressure (RAP) versus the capillary wedge pressure (CWP) with a ratio =0.65, detected with right heart catheterization performed after stable medical therapy according to international guidelines and comprehensive of loop diuretic (equivalent to furosemide oral dose till 2.0 mg/kg/day), coupled with urinary sodium excretion = mEq/L, confirmatory of loop diuretic resistance.
• Cava vein enlargement (inner diameter, detected with focused echocardiography, between 1,5 and 2,5 cm, with respiratory collapse <50% or absent due to intravascular fluid overload)
• Decreased kidney function addressed by the measurement of glomerular filtration rate (GFR) urea clearance + creatinine clearance/2 (>15 ml/min/1,73 m2)
• NT pro-BNP plasma concentration > 1000 pg/ml or BNP plasma concentration > 250 pg/ml
• at least one episode of pulmonary or systemic congestion requiring high-dose intravenous diuretics (or diuretic combinations) in the 6 months befor the study enrollment
• An appropriate PUF technique candidate.
• Signed informed consent

Exclusion Criteria:

• Recipients of heart transplantation
• Presence of a mechanical circulatory support device;
• Hypertrophic obstructive cardiomyopathy;
• Uncontrolled hypertension with systolic blood pressure = 160 mmHg
• Severe valvular stenosis;
• Restrictive cardiomyopathy;
• Acute coronary syndrome = 6 months before;
• Active myocarditis
• Cardiosurgical or Endo-radiological heart procedures = 6 months before
• Cardiac resynchronization therapy (CRT) implantation or upgrading of pacemaker (PM) or implantable cardioverter defibrillator (ICD) to CRT = 6 months before;
• Patient with end-stage renal disease, GFR urea clearance + creatinine clearance/2 (<15 ml/min/1,73 m2 GFR)
• Any major organ transplant (liver, lung, kidney)
• Lung embolism = 6 months before;
• Fibrotic lung disease;
• Liver Cirrhosis;
• Absolute contraindication to peritoneal catheter implantation;
• Logistical and or organizational contra-indication to treatment
• Active malignancy;
• Female patients who are pregnant or breast-feeding or who wish to become pregnant during the period of the clinical trial and for three months later
• Female patients of childbearing age who do not use adequate contracteption.
• Unwilling and unable to give informed consent;
• Enrolment in another clinical trial involving medical or device based interventions.
• Hypersensibility to IMP components.
• Evidence of any condition that, according to the investigators' judgment, could expose the subject to undue risk and/or prevent the subject from participating in the study procedures and/or potentially afftecting the study quality data.

Related Conditions & MeSH terms

• Cardio-Renal Syndrome
• Congestive Heart Failure
• Heart Failure

Intervention

Drug:
• PolyCore (Polydextrin, L-Carnitine, D-xylitol)
A single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours. Patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change.

Locations

Country	Name	City	State
Italy	Ospedale Ss. Annunziata	Chieti
Italy	ASST FBF Sacco	Milano
Italy	Ospedale Monaldi	Napoli

Sponsors (1)

Lead Sponsor	Collaborator
Iperboreal Pharma Srl

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite end-point of mortality and worsening patient's condition	patient's mortality - or; the need of increasing of =50% the initial daily dose of loop diuretic - or; the hospitalization for infusional therapy with loop diuretic based on the lack of adequate response to maximal dose of oral furosemide (>2.5 mg/kg/day) - or; requiring other methods of treatment [i.e. PUF or hemodialysis], based on persistence of high venous congestion (detected with central venous pressure measurement: >8 mm Hg or dilated inferior cava vein, without respiratory change, measured with focused abdominal echography, and coupled with body weight increase of 1 kg or more in the last 24 hrs.	Up to 7 months from randomization
Secondary	6 min Walking distance	Change from the baseline	At 3, 6 and 7 months from randomization
Secondary	Quality of life tested with Kansas City Cardiomyopathy Questionnaire (KCCQ)	Change from the baseline	At 3, 6 and 7 months from randomization
Secondary	Number of patients with decrease of NT pro-BNP (N-terminal pro brain natriuretic peptide)	The number of patients with a decrease in NT pro-BNP level of =25% from baseline	At 3, 6 and 7 months from randomization
Secondary	Worsening of renal function	Estimated Glomerular Filtration Rate (eGFR) =20 ml/min	Up to 7 months from randomization
Secondary	Cumulative daily dosage of loop diuretic	Change over the 6 months of study treatment,	Up to 7 months from randomization
Secondary	Use of hospital resources	The number of days spent in-hospital because of HF exacerbation during the 6 months of study treatment	Up to 7 months from randomization
Secondary	New York Heart Association (NYHA) class	Change from baseline	At 3, 6 and 7 months from randomization and during long-term FUs
Secondary	Number of patients requiring hospitalization	Hospitalization for infusional therapy with loop diuretic	Up to 7 months from randomization
Secondary	Number of patients increasing of =50% the initial daily dose of loop diuretic	Change from baseline	Up to 7 months from randomization
Secondary	Adverse Events	Information about all adverse events, whether volunteered by the patient, discovered by investigator questioning, or detected through physical examination, laboratory or instrumental test, will be collected, recorded and followed as appropriate.	through study completion, an average of 1 year